CureFAKtor Pharmaceuticals is a biotechnology focused on developing treatments for cancer based on research involving the role of the Focal Adhesion Kinase (FAK) protein. FAK is over-expressed in tumors and plays a role in facilitating the growth and spread of tumors, as well as tumor resistance to chemotherapeutic drugs and radiation. The company's products target FAK to treat pancreatic, breast, colon, melanoma, lung and brain oncology disorders. CureFAKtor is planning a Phase I clinical study of its CFAK-C4 treatment in combination with gemcitabine chemotherapy for pancreatic cancer.